177 related articles for article (PubMed ID: 21537551)
1. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
3. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
4. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.
Phabphal K; Geater A; Limapichart K; Sathirapanya P; Setthawatcharawanich S
Seizure; 2013 Mar; 22(2):103-8. PubMed ID: 23159358
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
[TBL] [Abstract][Full Text] [Related]
8. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy.
Twardowschy CA; Werneck LC; Scola RH; Borgio JG; De Paola L; Silvado C
Seizure; 2013 Apr; 22(3):194-7. PubMed ID: 23298603
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
10. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
11. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
12. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.
Ramasamy K; Narayan SK; Chanolean S; Chandrasekaran A
Neurol India; 2007; 55(4):408-9. PubMed ID: 18040121
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
15. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics: reality or fiction? Or are we there yet?
Lopes-Cendes I; Guerreiro CA
Arq Neuropsiquiatr; 2011 Apr; 69(2A):151-2. PubMed ID: 21537550
[No Abstract] [Full Text] [Related]
17. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Lee AY; Kim MJ; Chey WY; Choi J; Kim BG
Eur J Clin Pharmacol; 2004 May; 60(3):155-9. PubMed ID: 15024534
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
19. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
20. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Chang WC; Hung SI; Carleton BC; Chung WH
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
